AbbVie Inc. — Q3 2026 Earnings Summary

Guidance and Future Outlook

• Updated full-year 2026 adjusted diluted EPS guidance range is $13.76 to $13.96, reflecting a $216 million acquired IPR&D and milestones expense.
• Previously announced full-year adjusted diluted EPS guidance excluding Q3 acquired IPR&D and milestones expense was $13.87 to $14.07.
• Updated Q3 2026 adjusted diluted EPS guidance range is $3.73 to $3.77, down from a previously announced range of $3.84 to $3.88 excluding the specific Q3 expense.
• The 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expenses that may be incurred beyond the third quarter of 2026, as these cannot be reliably forecasted.
• The total acquired IPR&D and milestones expense for the full year 2026 is projected at $1,251 million.

Other Key Points

• The Q3 2026 acquired IPR&D and milestones expense of $216 million resulted in a $0.11 per share reduction to the adjusted diluted EPS guidance.
• The full-year 2026 acquired IPR&D and milestones expense of $1,251 million results in a $0.11 per share reduction to the adjusted diluted EPS guidance.